Serological pattern of hepatitis B virus among HBsAg negative blood donors in Alexandria, Egypt

El‐Ghitany, Engy Mohamed; Farghaly, Azza Galal

doi:10.26719/2013.19.7.600

Cited by 6 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A more recent study put the associated circulating HBV DNA level at <100 IU/ml [7]. El-Ghitany et al in a study reported that in OBI HBV DNA detection in serum or hepatocytes of HBsAg-negative/anti-HBc (IgG)-positive donors may be with or without other markers [33]. Absence of HBV DNA in isolated anti-HBc-positive blood donors in this study would have implied 0% OBI prevalence based on anti-HBc screening alone.…”

Section: Discussionmentioning

confidence: 99%

Isolated serum hepatitis B core antibody seropositivity: A diagnostic risk factor for occult hepatitis B infection

Fasakin

Ifeanyichukwu

Ibijola

et al. 2019

ISBT Science Series

View full text Add to dashboard Cite

Anti‐HBc screening and nucleic acid testing for hepatitis B viral DNA (HBV DNA) detection in blood donors are not routinely performed in clinical settings in Nigeria. This raises serious concerns for safety of blood at a time that global health standards advocate for transfusion safety. The aim of this research is to investigate if presence of anti‐HBc in blood donors is actually associated with occult hepatitis B infection through basic and advanced procedures. Prospective blood donors who were seronegative for HBsAg but sero‐positive for anti‐HBc (with or without other markers) among the four hundred and seventy enrolled in a cross‐sectional study were selected for this study. Samples were further screened for hepatitis B core immunoglobulin M by enzyme‐linked immunosorbent assay. Nucleic acid testing was performed for confirmation of occult hepatitis B infection. Anti‐HBc was detected in 20 (32.8%) of the sixty‐one HBsAg antigen‐negative blood donors which constituted 13.0% of the total number of enrolled blood donors. Anti‐HBc total‐positive differentiation showed eighteen (90.0%) anti‐HBc (IgG) and two (10%) anti‐HBc (IgM) were detected. Nucleic acid testing showed 5.0% prevalence of occult hepatitis B infection among the anti‐HBc‐positive blood donors with estimated HBV DNA viral load of 58 IU/ml. Demonstration of 5.0% occult hepatitis B prevalence showed the possibility of post‐transfusion hepatitis B infection in transfusion recipients with consequent possible liver damage should hepatitis B surface antigen alone be the continued practice in clinical settings. The inclusion of antibody to hepatitis B core antigen screening in addition to hepatitis B surface antigen marker is an essential step to ensuring optimal blood safety and prevent post‐transfusion hepatitis.

show abstract

Section: Discussionmentioning

confidence: 99%

Isolated serum hepatitis B core antibody seropositivity: A diagnostic risk factor for occult hepatitis B infection

Fasakin

Ifeanyichukwu

Ibijola

et al. 2019

ISBT Science Series

View full text Add to dashboard Cite

show abstract

Prevalence of antibody to hepatitis B surface antigen among qualified blood donors in Nanjing, China

Zhou

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Anti-HBs Seroprevalence in Blood Donors from Tyrol, Austria

Seekircher,

Mühlbacher,

Tschiderer

et al. 2024

Vaccines

View full text Add to dashboard Cite

Background/Objectives: Antibodies against the hepatitis B surface antigen (anti-HBs) are a marker of immunity against hepatitis B virus (HBV) infections. There is uncertainty about the anti-HBs seroprevalence in the general population of Austria. Methods: We conducted a cross-sectional analysis in blood donors from the Federal State of Tyrol in Austria (August–September 2023) to estimate anti-HBs seroprevalence and median antibody levels. Results: We enrolled 3935 blood donors (median age 47.6 years [25th–75th percentile: 33.3–56.6]; 40.7% female), who were hepatitis B surface antigen negative and had no detectable HBV-DNA. Overall seroprevalence was 51.4% (95% CI: 49.8–52.9%). Anti-HBs seropositivity decreased with higher age (p < 0.001), with 70.3% (66.1–74.3%) being seropositive among participants < 25 years of age and 30.2% (24.2–36.9%) in those aged ≥ 65 years. More females than males were seropositive (54.3% [51.8–56.7%] vs. 49.4% [47.4–51.4%]; p = 0.003). Seroprevalence was significantly higher in urban than in rural areas in participants aged 40 to <55 (p = 0.045) and ≥55 years (p = 0.001). Among 2022 seropositive participants, the overall median anti-HBs antibody level was 539.3 IU/L (25th–75th percentile: 116.3–5417.0). Furthermore, 5% of the participants had an anti-HBs antibody level between 10 and <20 IU/L, 18% between 20 and <100 IU/L, and 77% ≥100 IU/L. Conclusions: Anti-HBs seroprevalence in blood donors from Tyrol, Austria, was 51.4% between August and September 2023 and differed across age, sex, and residence area. Catch-up vaccination programs, especially targeting the elderly living in rural areas, are needed to close HBV immunity gaps.

show abstract

Serological pattern of hepatitis B virus among HBsAg negative blood donors in Alexandria, Egypt

Cited by 6 publications

References 28 publications

Isolated serum hepatitis B core antibody seropositivity: A diagnostic risk factor for occult hepatitis B infection

Isolated serum hepatitis B core antibody seropositivity: A diagnostic risk factor for occult hepatitis B infection

Prevalence of antibody to hepatitis B surface antigen among qualified blood donors in Nanjing, China

Anti-HBs Seroprevalence in Blood Donors from Tyrol, Austria

Contact Info

Product

Resources

About